SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 176.85M
March 31, 2026 171.62M
December 31, 2025 155.10M
September 30, 2025 150.61M
June 30, 2025 141.96M
March 31, 2025 98.77M
December 31, 2024 63.80M
September 30, 2024 28.94M
June 30, 2024 0.00
March 31, 2024 0.00
December 31, 2023 0.00
September 30, 2023 0.00
June 30, 2023 0.00
March 31, 2023 0.00
December 31, 2022 0.00
September 30, 2022 0.00
June 30, 2022 0.00
March 31, 2022 0.00
December 31, 2021 0.00
Date Value
September 30, 2021 0.00
June 30, 2021 0.00
March 31, 2021 0.00
December 31, 2020 0.00
September 30, 2020 0.00
June 30, 2020 0.00
March 31, 2020 0.00
December 31, 2019 0.00
September 30, 2019 0.00
June 30, 2019 0.00
March 31, 2019 0.00
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017 0.00
September 30, 2017 0.00
June 30, 2017 0.00

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Xencor, Inc. 65.28M
MeiraGTx Holdings Plc 52.16M
Insmed, Inc. 893.58M
Ironwood Pharmaceuticals, Inc. 64.55M
Viking Therapeutics, Inc. 50.70M